Molecular diagnostics company Co-Diagnostics, Inc. has received USD 1.2 million in funding from the National Institutes of Health (NIH) through the RADx Tech program. This brings the total funds raised by the company to USD 6.2 million.
The funds will be used to finalize the development of the company’s flu A/B, Covid-19, and RSV multiplex test and prepare for clinical trials on the Co-Dx PCR Home platform. The company also plans to submit the platform to the FDA and launch the Covid-19 test as its initial product.
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. Its Co-Dx PCR Home platform utilizes nucleic acid detection and analysis to create tests for infectious diseases, including Covid-19. The company aims to make high-quality and affordable diagnostics more accessible globally.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.